EpiVax Receives $600,000 Grant to develop treatment for Diabetes from National...
Centre Daily Times: 1 views since Tuesday, July 8, 2008 at 09:15 AM
EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop "Epi-13", a novel therapeutic for the prevention and treatment of Type 1 diabetes, a devastating and chronic autoimmune disease that affects ...

Published in: Institutes